Literature DB >> 25563720

Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients.

Vincent Wai-Sun Wong1, Pietro Lampertico, Victor de Lédinghen, Pik Eu Chang, Seung Up Kim, Yongpeng Chen, Henry Lik-Yuen Chan, Giampaolo Mangia, Juliette Foucher, Wan Cheng Chow, Sang Hoon Ahn, Jinlin Hou.   

Abstract

BACKGROUND: Liver stiffness measurement (LSM) by transient elastography is a popular noninvasive test of fibrosis. Traditional LSM cutoffs dichotomize patients and do not clearly indicate the confidence of diagnosis. AIM: We derived and validated probability functions of fibrosis and cirrhosis based on LSM and determined the effect of alanine aminotransferase (ALT) on the scores.
METHODS: Consecutive chronic hepatitis B patients who underwent liver function tests, LSM, and liver biopsies at six European and Asian centers (2/3 in the training cohort and 1/3 in the validation cohort) were recruited. Binary logistic regression was performed to predict the probabilities of different fibrosis stages based on LSM and/or ALT.
RESULTS: A total of 1,051 patients were included in the final analysis (53 % with ALT ≥ 60 IU/L, 32 % F2, 20 % F3, and 24 % F4). The probability functions (LiFA-HBV score) with and without ALT adjustment closely mirrored the proportion with different fibrosis stages in both the training and validation cohorts. For a range of up to 300 IU/L, ALT maintained a weak linear relationship with LSM for each fibrosis stage (r (2) = 0.018-0.13). Based on relative integrated discrimination improvement, the addition of ALT to the LiFA-HBV score increased the correct reclassification of F3-4 and F4 by 5 and 17 %, respectively.
CONCLUSIONS: ALT increases LSM in a linear fashion in chronic hepatitis B patients at any fibrosis stage. The LiFA-HBV score accurately predicts the probability of fibrosis. ALT adjustment increases the rate of reclassification modestly and is not essential.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563720     DOI: 10.1007/s10620-014-3488-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease.

Authors:  Mirella Fraquelli; Cristina Rigamonti; Giovanni Casazza; Dario Conte; Maria Francesca Donato; Guido Ronchi; Massimo Colombo
Journal:  Gut       Date:  2007-01-25       Impact factor: 23.059

2.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

3.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.

Authors:  Jorg Petersen; Vlad Ratziu; Maria Buti; Harry L A Janssen; Ashley Brown; Pietro Lampertico; Jan Schollmeyer; Fabien Zoulim; Heiner Wedemeyer; Martina Sterneck; Thomas Berg; Christoph Sarrazin; Marc Lutgehetmann; Peter Buggisch
Journal:  J Hepatol       Date:  2011-10-26       Impact factor: 25.083

4.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

5.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).

Authors:  Kyu Sik Jung; Seung Up Kim; Sang Hoon Ahn; Young Nyun Park; Do Young Kim; Jun Yong Park; Chae Yoon Chon; Eun Hee Choi; Kwang-Hyub Han
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

6.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

7.  Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B.

Authors:  James Fung; Ching-Lung Lai; Charles Cheng; Ringo Wu; Danny Ka-Ho Wong; Man-Fung Yuen
Journal:  Am J Gastroenterol       Date:  2010-12-14       Impact factor: 10.864

8.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

Authors:  Vincent Wai-Sun Wong; Stephen Lam Chan; Frankie Mo; Tung-Ching Chan; Herbert Ho-Fung Loong; Grace Lai-Hung Wong; Yanni Yan-Ni Lui; Anthony Tak-Cheung Chan; Joseph Jao-Yiu Sung; Winnie Yeo; Henry Lik-Yuen Chan; Tony Shu-Kam Mok
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

9.  Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.

Authors:  H L-Y Chan; G L-H Wong; P C-L Choi; A W-H Chan; A M-L Chim; K K-L Yiu; F K-L Chan; J J-Y Sung; V W-S Wong
Journal:  J Viral Hepat       Date:  2008-07-28       Impact factor: 3.728

10.  FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis.

Authors:  Jing-Houng Wang; Chi-Sin Changchien; Chao-Hung Hung; Hock-Liew Eng; Wei-Chih Tung; Kwong-Ming Kee; Chien-Hung Chen; Tsung-Hui Hu; Chuan-Mo Lee; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2009-03-25       Impact factor: 7.527

View more
  6 in total

1.  Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore.

Authors:  Pik Eu Chang; Juanda Leo Hartono; Yee Lin Ngai; Yock Young Dan; Kieron Bl Lim; Wan Cheng Chow
Journal:  Singapore Med J       Date:  2018-12-17       Impact factor: 1.858

Review 2.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

4.  Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard.

Authors:  Yi Xiang Zheng; Shu Juan Ma; Meng Hou Lu
Journal:  Hepat Mon       Date:  2016-02-16       Impact factor: 0.660

Review 5.  Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

Authors:  Grace Lai-Hung Wong; Wendell Zaragoza Espinosa; Vicnent Wai-Sun Wong
Journal:  Clin Mol Hepatol       Date:  2015-09-30

6.  Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B.

Authors:  Ja Yoon Heo; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Hyon-Suk Kim; Young Nyun Park; Kwang-Hyub Han; Kijun Song; Seung Up Kim
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.